Sep 30

2nd International Ataxia Research Conference

  • Palazzo dei Congressi

Retrotope will present results from its First-in-Human Phase 1b/2a clinical trial in 18 patients with Friedreich's ataxia. Another study will be presented which reveals strong correlations among four metrics of disease progression in FA.

Apr 28

AAN Annual Meeting - American Academy of Neurology

  • Boston Convention and Exhibition Center

Retrotope willl make a presentation entitled:

RT001 First-in Human Clinical Trial Demonstrates Safety, Favorable Pharmacokinetics, and Early Signals of Efficacy in Friedreich’s Ataxia

Apr 28

AAN Annual Meeting - American Academy of Neurology

  • Boston Convention and Exhibition Center

Retrotope will make a poster presentation entitled:

Isotope-Reinforced Polyunsaturated Lipids (D-PUFA) Mitigate Symptoms in Diverse Alzheimer’s Mouse Models

1:30 pm13:30

Lipid Peroxidation-Resistant Polyunsaturated Fatty Acids (PUFA)

  • Chemistry and Biochemisty UCLA

Founder and Chief Scientist Misha Shchepinov will present:

PUFAs are essential nutrients vital for biological, particularly mitochondrial and neuronal, membranes. Unlike any other type of oxidative stress-related damage, lipid peroxidation is a chain process which, once initiated, can damage thousands of PUFA residues before the reaction is terminated. The rate limiting step of the process is hydrogen abstraction at the bis-allylic (between double bonds) site. Antioxidants are inefficient for various reasons. A novel approach employs deuteration of PUFAs at the bis-allylic positions to stops lipid peroxidation by inhibiting the rate limiting step (hydrogen abstraction) due to the isotope effect. Numerous cell culture and animal studies, as well as Phase I in humans, support the role of LPO in neurological and other diseases, and offer a novel therapeutical intervention.

9:00 am09:00

FARA Biomarker Symposium

  • USF Sam and Martha Gibbons Alumni Center

Retrotope Chairman Dr. Harry J. Saal will present an

"Analysis of Correlations Observed Among Exercise and Neuro Evaluations of 18 FA Patients."

5:00 pm17:00

Understanding Energy for a Cure Symposium

  • USF Sam and Martha Gibbons Alumni Center

Retrotope will be a presenter at this Symposium.

"Join USF Ataxia Research Center leadership, Dr. Theresa Zesiewicz MD., FAAN, along with FARA Executive Director, Jennifer Farmer and President, Ronald Bartek for a special interactive symposium focused on advancing therapeutic approaches. The symposium will feature updates for ongoing clinical trials along with drug discovery efforts targeting the root cause of this genetic disease. Top researchers will share insights into emerging treatments for Friedreich’s Ataxia. A special panel of individuals living with FA will also share their experiences and perspectives."

Sep 8

57th International Conference on the Bioscience of Lipids (ICBL)

  • Congress Centre « LE MAJESTIC »

Retrotope CSO Misha Shchepinov will present a paper titled

"Lipid Peroxidation-Resistant Polyunsaturated Fatty Acids (PUFA)"

at the "Non-enzymatic lipid oxidation" session which is scheduled for

Wednesday, Sept. 7th.

Jul 25

Drug Discovery & Therapy World Congress 2015

  • John Hynes Memorial Convention Center

Presentation of "Deuterated Polyunsaturated Fatty Acids (dPUFAs) overcome lipid peroxidation damage in CNS disorders" by Lex Van der Ploeg, Charles Cantor, Robert De Jager, Harry Saal, Bob Molinari and Misha Shchepinov. (Retrotope, Inc.)

May 7

Oxford Rare Disease Conference 2015

  • St Anne’s College

Mikhail Shchepinov, Chief Scientific Officer, Retrotope Inc. will present "Mitigating Neurological Diseases with Isotope Reinforced PUFAs" at 0930 on 7 May, 2015.

Mar 28

International Ataxia Research Conference 2015

  • Beaumont Estate

Retrotope, Inc., an emerging, clinical stage degenerative disease therapeutic company, gave a presentation at the International Ataxia Research Conference.  The talk entitled: “An upcoming clinical trial testing the safety and efficacy of a stabilized polyunsaturated fatty acid in Friedreich’s ataxia” elucidated the company’s progress towards an Investigational New Drug (IND) application for the fatal, orphan disease, Friedreich’s ataxia (FRDA).   Currently, there is no approved therapy for FRDA. See the News section for further details.